The marked elevation of aminotransferase enzyme ALT is a major precursor for the subsequence phase of nonalcoholic fatty liver disease, hepatic steatohepatitis, and liver diseases. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.